Literature DB >> 16832584

Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.

Anderson Alves da Rocha1, Ricardo Rodrigues Giorgi, Sandra Valeria de Sa, Maria Lucia Correa-Giannella, Maria Angela Fortes, Ana Mercedes Cavaleiro, Marcio Carlos Machado, Valter Angelo Cescato, Marcello Delano Bronstein, Daniel Giannella-Neto.   

Abstract

Pituitary tumors, adenomas in their vast majority, represent around 10-15% of the intracranial neoplasms. Pituitary carcinomas are exceedingly rare. Clinically, these neoplasms cause hormonal dysfunctions, and mass effect symptoms as headache and visual disorders in the case of macroadenomas. Pituitary tumorigenesis is still poorly understood. In order to investigate the expression of cancer-related genes in pituitary tumors, we employed a human cancer cDNA macroarray membrane with 1176 well-characterized human genes related to cancer and tumor biology. We were able to identify several differentially expressed genes, among them hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) which were over expressed in a pool of clinically nonfunctioning pituitary adenomas, compared with a spinal cord metastasis of a nonfunctioning pituitary carcinoma. HGS and GUK1 mRNA expression were chosen to be validated by quantitative RT-qPCR, however, only GUK1 had the differential expression confirmed between the adenomas and the metastasis of a pituitary carcinoma. We have also investigated HGS and GUK1 mRNA expressions in a series of 46 pituitary adenomas (18 nonfunctioning, 12 GH-secreting, nine PRL-secreting, and seven ACTH-secreting adenomas). HGS and GUK1 were significantly over expressed in GH-secreting adenomas, compared with ACTH-secreting adenomas and nonfunctioning tumors, and with PRL-secreting adenomas, respectively. We have shown that these genes, involved in tumorigenesis in other tissues, are as well over expressed in the pituitary tumors, however, their role in the oncogenesis of these tumors need to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832584     DOI: 10.1007/s11102-006-9277-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  40 in total

Review 1.  Guanylyl cyclases and signaling by cyclic GMP.

Authors:  K A Lucas; G M Pitari; S Kazerounian; I Ruiz-Stewart; J Park; S Schulz; K P Chepenik; S A Waldman
Journal:  Pharmacol Rev       Date:  2000-09       Impact factor: 25.468

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

3.  Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).

Authors:  X Zhang; G A Horwitz; T R Prezant; A Valentini; M Nakashima; M D Bronstein; S Melmed
Journal:  Mol Endocrinol       Date:  1999-01

Review 4.  The cytogenesis and pathogenesis of pituitary adenomas.

Authors:  S L Asa; S Ezzat
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 5.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 6.  Diagnosis and management of nonfunctioning pituitary tumors.

Authors:  Y Greenman; S Melmed
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

7.  Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a structurally conserved putative zinc finger domain.

Authors:  M Komada; N Kitamura
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

8.  Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.

Authors:  J McAndrew; A J Paterson; S L Asa; K J McCarthy; J E Kudlow
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

9.  A role for Hrs in endosomal sorting of ligand-stimulated and unstimulated epidermal growth factor receptor.

Authors:  Chitose Morino; Masaki Kato; Akitsugu Yamamoto; Emi Mizuno; Akira Hayakawa; Masayuki Komada; Naomi Kitamura
Journal:  Exp Cell Res       Date:  2004-07-15       Impact factor: 3.905

10.  p53 gene mutations in pituitary adenomas: rare events.

Authors:  A Levy; L Hall; W A Yeudall; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

View more
  3 in total

Review 1.  Genetic aspects of pituitary carcinoma: A systematic review.

Authors:  Zijiang Yang; Ting Zhang; Heng Gao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer.

Authors:  Sigurdur Trausti Karvelsson; Qiong Wang; Bylgja Hilmarsdottir; Arnar Sigurdsson; Siver Andreas Moestue; Gunhild Mari Mælandsmo; Skarphedinn Halldorsson; Steinn Gudmundsson; Ottar Rolfsson
Journal:  NPJ Syst Biol Appl       Date:  2021-09-17

3.  A signal-based method for finding driver modules of breast cancer metastasis to the lung.

Authors:  Gaibo Yan; Vicky Chen; Xinghua Lu; Songjian Lu
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.